Alpha -Tocopherol Acetate Silicon Dioxide Sodium P

證據等級: L5

預測適應症: 0 個

Alpha-Tocopherol Acetate Combination: Unable to Generate Repurposing Evaluation

One-Sentence Summary

The queried entry .ALPHA.-TOCOPHEROL ACETATE; SILICON DIOXIDE; SODIUM PYROPHOSPHATE appears to be a multi-ingredient raw material or excipient listing rather than a single drug entity suitable for repurposing evaluation. The TxGNN model returned no predicted indications for this entry, and no US market authorization records were found. As a result, a standard repurposing evaluation cannot be completed at this time.

Quick Overview

Item	Content
Original Indication	None on record
Predicted New Indication	None — TxGNN returned no predictions
TxGNN Prediction Score	N/A
Evidence Level	L5 (model prediction only — not applicable; no predictions generated)
US Market Status	Not marketed
Number of NDAs	0
Recommended Decision	Hold

Why No Prediction Was Generated

The query string contains three distinct components:

Component	Role
Alpha-Tocopherol Acetate	Pharmacologically active — esterified form of Vitamin E; antioxidant
Silicon Dioxide	Pharmaceutical excipient — anti-caking / flow agent; no therapeutic activity
Sodium Pyrophosphate	Pharmaceutical excipient / food additive — buffering/sequestrant agent; no therapeutic activity

Because TxGNN’s knowledge graph operates on single drug entities mapped to DrugBank identifiers, a compound query string containing excipients alongside an active ingredient cannot be resolved to a valid DrugBank node. No DrugBank ID was assigned (drugbank_id: null), and consequently no knowledge-graph traversal or deep-learning inference was performed.

If a repurposing evaluation is intended for Vitamin E (alpha-tocopherol acetate) specifically, the query should be resubmitted using the single INN alpha-tocopherol acetate or its DrugBank identifier DB00163, separately from the excipient components.

Safety Considerations

No safety data is available for this entry. Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: The Evidence Pack could not be evaluated because the drug entry is a multi-ingredient excipient mixture without a valid DrugBank mapping, and TxGNN returned zero predicted indications. There is no actionable repurposing signal to assess.

To proceed, the following is needed:

Resubmit as a single-entity query: Use alpha-tocopherol acetate (DrugBank DB00163) as the sole drug identifier, omitting excipients (silicon dioxide, sodium pyrophosphate)
Confirm the clinical question: Clarify whether the intent is to repurpose Vitamin E for a new therapeutic indication, or whether this entry was submitted in error
Retrieve MOA data: Query DrugBank API for DB00163 to obtain mechanism of action, pharmacodynamics, and indication data
Re-run TxGNN pipeline: After correcting the drug identifier, re-execute KG and DL predictions to obtain ranked indication candidates
TFDA package insert review: If a Taiwan-marketed Vitamin E product exists under a different trade name, retrieve the full product monograph for safety pre-screening
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.